 MOUNTAIN VIEW, Calif., Nov. 30, 2020 GLOBE NEWSWIRE -- IGM Biosciences, Inc. Nasdaq: IGMS, a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Companys Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology ASH Annual Meeting and Exposition. 